Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

4,4'-DMAR

This article is a stubmissing:
Subjective Effects
Pharmacology
Interactions
Tolerance
History & Culture
4,4'-DMAR molecule structure4,4'-DMAR molecule structure
4,4'-Dimethylaminorex
Serotoni, para-methyl-4-methylaminorex
Psychoactive Class
Chemical Class
Aminorex

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~30 mg
Light30-60 mg
Moderate60-120 mg
Strong120-200 mg
Heavy200+ mg

Duration

After Effects1-12 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacology not written up yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Toxicity

Lethal Dosage

At least 31 deaths have been linked to 4,4'-DMAR in Hungary, Poland, and the UK by February 2014, with an additional 19 deaths reported in Northern Ireland during the same period. Most fatalities occurred when the substance was consumed in combination with other drugs.

History & Culture

History & Culture not written up yet

Legality

By Country

Illegal2
United States flagUnited StatesIllegal
Germany flagGermanyIllegal

References

Source Pages

  1. Bluelight: Thread on 4,4'-DMAR
  2. Erowid:
  3. Erowid: References
  4. Erowid: References on 4,4'-DMAR
  5. The Drug Classroom
  6. Wikipedia
  7. Wikipedia: 4,4'-Dimethylaminorex

Citations

Further Reading

  1. EMCDDA: Joint Report on 4,4'-DMAR
  2. Federal Register: DEA Scheduling
  3. PubChem:
  4. PubMed: 4,4'-DMAR Web-based study
  5. PubMed: Pharmacological characterization of aminorex analogs

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 4,4'-DMAR article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.